China Resources Double-Crane Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 600062.SS

China Resources Double-Crane Pharmaceutical Co.,Ltd. Price to Book Ratio (P/B) on January 14, 2025: 1.73

China Resources Double-Crane Pharmaceutical Co.,Ltd. Price to Book Ratio (P/B) is 1.73 on January 14, 2025, a 3.03% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • China Resources Double-Crane Pharmaceutical Co.,Ltd. 52-week high Price to Book Ratio (P/B) is 13.48 on December 20, 2024, which is 678.78% above the current Price to Book Ratio (P/B).
  • China Resources Double-Crane Pharmaceutical Co.,Ltd. 52-week low Price to Book Ratio (P/B) is 1.53 on January 22, 2024, which is -11.53% below the current Price to Book Ratio (P/B).
  • China Resources Double-Crane Pharmaceutical Co.,Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 1.94.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Loading...
Shanghai Stock Exchange: 600062.SS

China Resources Double-Crane Pharmaceutical Co.,Ltd.

CEO Mr. Wenchao Lu
IPO Date May 22, 1997
Location China
Headquarters No. 1, Lize East 2nd Road
Employees 12,269
Sector Health Care
Industries
Description

China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People's Republic of China. The company offers soft bag, plastic and glass bottle, inner sealed polypropylene, and polypropylene blend bag infusion products; levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, sodium chloride injection products, etc.; and peritoneal dialysate, hemodialysis dialysate, etc. It also provides compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, edaravone, and other products to treat cardiovascular and cerebrovascular diseases. In addition, the company offers products for endocrinology; and pediatric compound amino acid injection, and other drugs to treat pediatrics. Further, it provides nutritional drugs, including vitamin E and C; and anti-infective drugs. The company is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. is a subsidiary of Beijing Pharmaceutical Group Co., Ltd.

Similar companies

600058.SS

Minmetals Development Co., Ltd.

USD 0.95

1.76%

600085.SS

Beijing Tongrentang Co., Ltd

USD 5.16

2.25%

600007.SS

China World Trade Center Co., Ltd.

USD 3.20

0.78%

600056.SS

China Meheco Group Co., Ltd.

USD 1.47

2.19%

600008.SS

Beijing Capital Eco-environment Protection Group Co.,ltd.

USD 0.42

1.31%

StockViz Staff

January 15, 2025

Any question? Send us an email